Oral influenza vaccine one step closer, says Vaxart
A seasonal flu vaccine taken in the form of an oral solid dose has been found comparable to currently available jabs, according to data presented by developer Vaxart.
Archives for October 21, 2014
EMA tells us it looks forward to continuing close relationship with DG SANCO
Juncked: Plan to move EMA from DG Health to DG Enterprise is abandoned
DG Health will keep responsibility for the EMA according to European Commission President-elect Jean-Claude Juncker, who confirmed plans to hand the agency to DG Enterprise have been abandoned.
Consultant: Commercial bioequivalence software in need of validation in wake of Thermo Scientific's review
A bioanalytical consultant has stressed the importance of drug developers testing commercial off-the-shelf (COTS) software following the discovery of potential issues with Thermo Scientific’s bioequivalence Kinetica platform.
NIH: without budget cuts, we’d have Ebola vaccine
The head of the US National Institutes of Health has said the organisation would have developed a finished Ebola vaccine by now if its funding had not been slashed over the last decade.
Mouse model firm Crown builds oncology centre
Animal-model contract research organisation (CRO) Crown Bioscience will open a research centre in North Carolina, combining expanded oncology services with its existing cardiovascular and metabolic offerings.
Icon has added biotech customers and entered new sectors through Aptiv say execs
Icon says it has signed more deals with biotech customers and is seeing more interest for adaptive trial designs.
Global TB drug development efforts underfunded says WHO
Janssen-Cilag’s bedaquiline and Otsuka’s delamanid notwithstanding, the drug industry is not spending enough on the development of tuberculosis medicines according to the WHO.
Dispatches from BioProcess International
Shift to single-use means end users ceding more control to suppliers, experts say
As single-use technology replaces traditional stainless steel technology in biomanufacturing, suppliers will own a larger portion of the supply chain, which is creating anxiety for end users such as Pfizer and Merck, experts say.